Document is current
Any future updates will be listed below
-
Authors
Douvaras, Panagiotis
Buenaventura, Diego F.
Sun, Bruce
Lepack, Ashley
Baker, Elizabeth
Simpson, Elizabeth
Ebel, Mark
Lallos, Gregory
LoSchiavo, Deven
Stitt, Nicholas
Adams, Nathaniel
McAuliffe, Conor
Forton-Juarez, Ana
Kosmyna, Brian
Pereira, Elizabeth
Burnett, Benjamin
Dilworth, David
Fisher, Stephanie
Wang, Jing
Tonge, Peter
Tomishima, Mark
Paladini, Carlos
Wilkinson, Dan
Soh, Chew-Li
Srinivas, Maya
Patsch, Christoph
Irion, Stefan https://orcid.org/0000-0002-0482-714X
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 2 September 2024
First Online: 16 September 2024
Competing interests
: All authors are current or past employees of BlueRock Therapeutics and have financial incentives to develop cellular medicines to reverse devastating diseases. All research was performed using BlueRock’s internal funds. BlueRock is a wholly-owned subsidiary of Bayer AG. There are no more competing interests.
